PHILLIP FROST - 19 Jan 2024 Form 4 Insider Report for BioCardia, Inc. (BCDA)

Role
10%+ Owner
Signature
/s/ Phillip Frost, MD, Individually and as trustee
Issuer symbol
BCDA
Transactions as of
19 Jan 2024
Net transactions value
-$55,815
Form type
4
Filing time
22 Jan 2024, 20:38:06 UTC
Previous filing
18 Jan 2024
Next filing
07 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCDA Common Stock Sale $55,815 -129,802 -6.4% $0.4300 1,896,025 19 Jan 2024 See footnote F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

PHILLIP FROST is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $0.38 to $0.57, inclusive. The price reported above reflects the weighted average sale price.
F2 On June 6, 2019, the Issuer effected a 1-9 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F3 These securities are held by Frost Gamma Investments Trust, of which the Reporting Person is the trustee. Frost Gamma Limited Partnership is the sole and exclusive beneficiary of Frost Gamma Investments Trust. The Reporting Person is one of two limited partners of Frost Gamma Limited Partnership. The general partner of Frost Gamma Limited Partnership is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation, of which the Reporting Person is the sole shareholder.